drugset / Trial / NCT02204397
Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis
NaSingle-groupOpen-labelTreatment
Summary
A proof-of-concept for safety and preliminary clinical efficacy of a combined regimen of INGAP-P for β-cell regeneration and ustekinumab for IL-12-23 autoimmune modulation in patients with established T1DM.
Timeline
- Start
- 2015-11
- Primary completion
- 2017-03-08
- Completion
- 2017-03-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INGAP Peptide | Peptide | 600 mg | Subcutaneous |
| Subject | Ustekinumab | Monoclonal antibody | 45 mg | Subcutaneous |